Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL.

Cell Rep. 2013 Sep 26;4(6):1090-9. doi: 10.1016/j.celrep.2013.08.023. Epub 2013 Sep 19.

2.

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, Gilmer TM, Parsons JT, Bauer TW.

Neoplasia. 2013 Feb;15(2):143-55.

3.

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.

Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM.

Mol Cancer Ther. 2012 Apr;11(4):909-20. doi: 10.1158/1535-7163.MCT-11-0989. Epub 2012 Mar 2.

4.

Lapatinib: functional genomics study leads to insights into mechanism of action.

Gilmer TM.

Mol Cancer Ther. 2011 Nov;10(11):2025. doi: 10.1158/1535-7163.MCT-11-0700. No abstract available.

5.

The discovery of lapatinib (GW572016).

Rusnak D, Gilmer TM.

Mol Cancer Ther. 2011 Nov;10(11):2019. doi: 10.1158/1535-7163.MCT-11-0697. No abstract available.

6.

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, Martin AM, Gilmer TM.

Mol Cancer Ther. 2011 Mar;10(3):518-30. doi: 10.1158/1535-7163.MCT-10-0698. Epub 2011 Jan 20.

7.

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM.

Cancer Res. 2009 Sep 1;69(17):6871-8. doi: 10.1158/0008-5472.CAN-08-4490. Epub 2009 Aug 11.

8.

Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.

Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH.

J Natl Cancer Inst. 2009 Jan 21;101(2):107-13. doi: 10.1093/jnci/djn436. Epub 2009 Jan 13.

9.

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C.

Clin Cancer Res. 2008 Dec 1;14(23):7900-8. doi: 10.1158/1078-0432.CCR-08-0415.

10.

The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).

Schilsky RL, Gordon G, Gilmer TM, Courtneidge SA, Matrisian LM, Grad O, Nelson WG; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5685-91. doi: 10.1158/1078-0432.CCR-08-1265.

11.

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.

Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R.

Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783.

12.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

13.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.

PMID:
17635524
14.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.

15.

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM.

Mol Cancer Ther. 2007 May;6(5):1629-40.

16.

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.

Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M.

Mol Cancer Ther. 2007 Feb;6(2):450-9. Epub 2007 Jan 31.

17.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.

18.

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L.

Cancer Res. 2004 Sep 15;64(18):6652-9.

19.

A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays.

Rusnak DW, Lai Z, Lansing TJ, Rhodes N, Gilmer TM, Copeland RA.

Bioorg Med Chem Lett. 2004 May 3;14(9):2309-12.

PMID:
15081030
20.

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

Gaul MD, Guo Y, Affleck K, Cockerill GS, Gilmer TM, Griffin RJ, Guntrip S, Keith BR, Knight WB, Mullin RJ, Murray DM, Rusnak DW, Smith K, Tadepalli S, Wood ER, Lackey K.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):637-40.

PMID:
12639547
21.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

22.

Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation.

Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, Platt A, Gilmer TM, Fu XY, Chin YE.

J Biol Chem. 2002 Aug 23;277(34):30716-23. Epub 2002 Jun 17.

23.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.

Cancer Res. 2001 Oct 1;61(19):7196-203.

24.

Expression and purification of active recombinant ATM protein from transiently transfected mammalian cells.

Rhodes N, Gilmer TM, Lansing TJ.

Protein Expr Purif. 2001 Aug;22(3):462-6.

PMID:
11483009
25.

Monoclonal antibodies generated against recombinant ATM support kinase activity.

Alligood KJ, Milla M, Rhodes N, Ellis B, Kilpatrick KE, Lee A, Gilmer TM, Lansing TJ.

Hybridoma. 2000 Aug;19(4):317-21.

PMID:
11001404
26.

Thirteenth Aspen Cancer Conference: workshop on mechanisms of toxicity and carcinogenesis.

Nesnow S, Cavanee W, Gilmer TM, Kaufman DG, Slaga TJ, Hohman R, Bishop JM, Poirier MC, Harris CC, Trump BF, Yuspa SH, Pfeifer AM, Sherman MI, Tennant R.

Mol Carcinog. 1999 Jun;25(2):99-106. No abstract available.

PMID:
10365911
27.

The formation of a covalent complex between a dipeptide ligand and the src SH2 domain.

Alligood KJ, Charifson PS, Crosby R, Consler TG, Feldman PL, Gampe RT Jr, Gilmer TM, Jordan SR, Milstead MW, Mohr C, Peel MR, Rocque W, Rodriguez M, Rusnak DW, Shewchuk LM, Sternbach DD.

Bioorg Med Chem Lett. 1998 May 19;8(10):1189-94.

PMID:
9871733
28.

Defective potassium currents in ataxia telangiectasia fibroblasts.

Rhodes N, D'Souza T, Foster CD, Ziv Y, Kirsch DG, Shiloh Y, Kastan MB, Reinhart PH, Gilmer TM.

Genes Dev. 1998 Dec 1;12(23):3686-92.

29.

Potent dipeptide inhibitors of the pp60c-src SH2 domain.

Pacofsky GJ, Lackey K, Alligood KJ, Berman J, Charifson PS, Crosby RM, Dorsey GF Jr, Feldman PL, Gilmer TM, Hummel CW, Jordan SR, Mohr C, Shewchuk LM, Sternbach DD, Rodriguez M.

J Med Chem. 1998 May 21;41(11):1894-908.

PMID:
9599239
30.

Twelfth Aspen Cancer Conference: mechanisms of toxicity and carcinogenesis.

Nesnow S, Harris CC, Trump BF, Mendelsohn ML, Dellarco V, Gilmer TM, Cavanee W, Tennant R.

Mol Carcinog. 1998 May;22(1):1-8. No abstract available.

PMID:
9609095
31.
32.

Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate.

Chen CY, Hall I, Lansing TJ, Gilmer TM, Tlsty TD, Kastan MB.

Cancer Res. 1996 Aug 15;56(16):3659-62.

33.

The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization.

Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB.

Am J Pathol. 1996 May;148(5):1381-5.

34.

Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers.

Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ.

Oncogene. 1996 Jan 4;12(1):169-76.

PMID:
8552388
35.

The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein.

Kilpatrick KE, Carrier F, Smith ML, Chen CY, Lee AJ, Rusnak DW, Kastan MB, Fornace AJ Jr, Champion BR, Gilmer TM, et al.

Hybridoma. 1995 Aug;14(4):355-9.

PMID:
8522347
36.

Growth factor modulation of p53-mediated growth arrest versus apoptosis.

Canman CE, Gilmer TM, Coutts SB, Kastan MB.

Genes Dev. 1995 Mar 1;9(5):600-11.

37.

Characterization of human Gadd45, a p53-regulated protein.

Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, Engelstein M, Friend SH, Henner WD, Gilmer TM, et al.

J Biol Chem. 1994 Dec 23;269(51):32672-7.

38.

Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.

Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ Jr.

Science. 1994 Nov 25;266(5189):1376-80.

PMID:
7973727
39.

ras mutations and expression in head and neck squamous cell carcinomas.

Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM.

Laryngoscope. 1994 Nov;104(11 Pt 1):1337-47.

PMID:
7968162
40.

Involvement of pp60c-src with two major signaling pathways in human breast cancer.

Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez M, Berman J, Gilmer TM.

Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):83-7.

41.

Unique chromosomal rearrangement and mucin production in a novel salivary myoepithelial cell strain.

Witsell DL, Weissler MC, Livanos E, Bova-Hill C, Gilmer TM.

Arch Otolaryngol Head Neck Surg. 1993 Oct;119(10):1151-7.

PMID:
8398066
42.

Overexpression of pp60c-src is associated with altered regulation of adenylyl cyclase.

Luttrell DK, Hausdorff WP, Moyers JE, Gilmer TM, Parsons SJ, Caron MG, Lefkowitz RJ.

Cell Signal. 1992 Sep;4(5):531-41.

PMID:
1384635
43.

Oncogene amplification in squamous cell carcinoma of the head and neck.

Merritt WD, Weissler MC, Turk BF, Gilmer TM.

Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1394-8.

PMID:
2248738
44.

Novel tyrosine phosphorylations accompany the activation of pp60c-src during chemical carcinogenesis.

Kanner SB, Gilmer TM, Reynolds AB, Parsons JT.

Oncogene. 1989 Mar;4(3):295-300.

PMID:
2468123
45.

Induction of gene amplification by arsenic.

Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett JC.

Science. 1988 Jul 1;241(4861):79-81.

PMID:
3388020
46.

Activation of pp60c-src tyrosine kinase specific activity in tumor-derived Syrian hamster embryo cells.

Kanner SB, Parsons SJ, Parsons JT, Gilmer TM.

Oncogene. 1988 Apr;2(4):327-35.

PMID:
2452399
47.
48.

In vitro analysis of multistage carcinogenesis.

Nettesheim P, Fitzgerald DJ, Kitamura H, Walker CL, Gilmer TM, Barrett JC, Gray TE.

Environ Health Perspect. 1987 Nov;75:71-9. Review.

49.

Correlation of V-src gene amplification with the tumorigenic phenotype in a Syrian hamster embryo cell line.

Gilmer TM, Lamb PW, Oshimura M, Barrett JC.

Cancer Res. 1987 Sep 1;47(17):4663-6.

50.

Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells.

Walker C, Nettesheim P, Barrett JC, Gilmer TM.

Proc Natl Acad Sci U S A. 1987 Apr;84(7):1804-8.

Supplemental Content

Loading ...
Support Center